Articles By Suzanne Elvidge

  1. Can Private Money Stop The Slump In Global R&D Funding?

    A closer analysis of the Brookings Institute’s Private Sector Investment in Global Health R&D: Spending Levels, Barriers, and Opportunities report.

  2. Alternatives To Funding Lower-Priority Trials

    While some pharma companies struggle to backfill their pipelines, others find the opposite, that they have more development opportunities than they can pursue. While this may seem to be a nice problem to have, it also means that otherwise good drug candidates may be pushed down the list of priorities.

  3. Bridging The Gap Between Academia, Small Biotechs, And Industry

    Academia and biotech have long been sources of innovation for the pharmaceutical industry, and this is increasingly important for Big Pharmas that want to prop up flagging pipelines or boost particular areas of focus.

  4. Women In Bio: Looking Through The Glass Ceiling

    “When I started in biopharma, attending research and business meetings, I was surprised by the overrepresentation of men. I had expected health to be a more feminized area,” says Karen Aiach, founder and CEO, Lysogene.

  5. The Increasing Importance Of Real-World Evidence In Drug Development

    Market access is all about getting the right drugs to the right patients at the right time and for the right price. But to do so, every pharma or biotech company must face a mounting set of challenges, including, most prominently, high research costs and tighter budgets.

  6. The Uphill Battle Toward Innovation For Antibiotic Resistance

    The discovery of antibiotics as a class of drugs, based on Alexander Fleming’s breakthrough in 1928, seemed like a miracle, with potential to rid people and animals of the scourge of bacterial infection. However, by 1947, just four years after the beginning of mass production of penicillin, the first penicillin-resistant strain of staphylococcus aureus had emerged.

  7. GW Pharmaceuticals Changes Its Focus To Rare Diseases

    The pharma company’s original focus was on the use of cannabis to relieve spasticity from MS, but now its pursuing rare and orphan indications, where there are limited or no other treatment options.

  8. The Evolution Of CRO Reimbursement: Shifting From Task-Driven Units To Desired Outputs

    Over the years, pharma and biotech companies have looked to create better models to speed drug development and make it quicker, more efficient, and more effective, and this includes using the specialist expertise in clinical research organizations to carry out clinical development.

  9. The Strength At The Interface: Academia Meets Biopharma Industry

    Collaborations between academia and industry are becoming more common as biopharma companies, both large and small, see the value gained from different approaches.

  10. Biotechnology In The U.K.: Growing And Changing

    The U.K. has a long heritage in life science and medicine. It’s biotech sector hopes to continue to build on that tradition.